Лортенза

Quick links

Choose a section

Quick links to important sections

Advertisements

Лортенза

Selected form

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Лортенза

Property Description
Active ingredients Amlodipine, Losartan
Form Fixed-Dose Combination Oral Tablets
Pharmacological class Antihypertensive Agent (CCB and ARB)
Common use Management of high blood pressure (Hypertension)
Origin Synthetic

What Type of Medicine is Лортенза and Its Composition?

Лортенза is a prescription-only synthetic drug entity primarily classified as an antihypertensive agent, intended for the management of high blood pressure in adults. Its structure is defined as a fixed-dose combination presented in Oral Tablets, integrating two distinct active ingredients: Amlodipine and Losartan. The use of this combination format simplifies the treatment regimen by ensuring the simultaneous delivery of both compounds—typically Amlodipine besylate and Losartan potassium—in a single dose. This fixed pairing of two agents from different classes is designed to optimize patient adherence compared to prescribing two separate tablets.

Understanding the Dual Mechanism Pharmacological Class

This medicine belongs to two separate pharmacological classes that provide a dual mechanism for blood pressure control. The Amlodipine component is a dihydropyridine calcium channel blocker (CCB), which acts by relaxing the blood vessels, while the Losartan component is an Angiotensin II receptor antagonist (ARB). Losartan works by blocking the action of a naturally occurring hormone in the body (Angiotensin II) that causes blood vessels to narrow. The synergistic action of these two agents is utilized in cases where high blood pressure management requires the influence of two separate physiological pathways.

Primary Purpose of the Amlodipine/Losartan Combination

The core therapeutic use of Лортенза is the long-term, sustained management of hypertension. The strategic pairing of these two agents is utilized for patients whose blood pressure is not adequately controlled by therapy using a single agent. This dual-acting formulation is intended to provide comprehensive control of blood pressure. By maintaining continuous management of blood pressure levels, the medicine's fundamental purpose is to mitigate the chronic strain on the cardiovascular system associated with sustained hypertension.

Advertisements

What side effects are possible with Лортенза?

Possible Side Effects and Safety Information

The safety profile for Losartan (Лортенза) is primarily based on regulatory clinical trials and post-marketing surveillance, identifying a range of adverse reactions and critical safety warnings.

Key Adverse Reactions

The most commonly reported adverse events (incidence 1%) across different studies include dizziness, upper respiratory infection, nasal congestion, back pain, fatigue, diarrhea, and hypoglycemia. However, the reported incidence of cough is generally lower than with ACE inhibitors.

Serious Safety Concerns

Official labeling highlights several serious and clinically significant adverse reactions that necessitate caution and monitoring:

  • Fetal Toxicity: Losartan is contraindicated in the second and third trimesters of pregnancy due to the risk of injury and death to the developing fetus.
  • Angioedema: Rapid swelling of the face, lips, throat, or tongue (allergic reaction) is a rare but potentially fatal side effect.
  • Hypotension: Severe low blood pressure may occur, particularly in patients who are volume- or salt-depleted (e.g., those on high-dose diuretics). Volume depletion must be corrected before treatment initiation.
  • Renal Function Deterioration and Hyperkalemia: Losartan may cause or worsen acute renal impairment and increase serum potassium levels (hyperkalemia), especially in patients with pre-existing kidney problems or heart failure. Close monitoring of kidney function and potassium levels is required.

Restrictions and Specific Population Safety

Losartan is contraindicated in patients with severe hepatic impairment or severe renal impairment (creatinine clearance < 30 ml/min). A lower initial dose is recommended for patients with mild-to-moderate hepatic impairment. Concomitant use with aliskiren-containing medicines is contraindicated in patients with diabetes or moderate-to-severe renal impairment (GFR < 60 ml/min/1.73 m^2). The safety data emphasize mandatory monitoring of blood pressure, serum potassium, and renal function.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Лортенза (Amlodipine/Losartan) overdose centers on the risk of severe cardiovascular compromise. Over-exposure to the medication is primarily characterized by profound and prolonged systemic hypotension due to excessive peripheral vasodilation, which may be accompanied by reflex tachycardia or, less frequently, bradycardia.

The most serious outcome documented is the development of shock, which may have a fatal outcome and necessitates urgent medical care. Official regulatory instructions mandate that individuals must seek immediate medical attention and contact emergency services if an overdose is suspected, particularly in the event of collapse, seizures, or difficulty breathing.

Overdose Management

Classification Management Approach
Antidote Availability No specific antidote is known for either Amlodipine or Losartan.
Supportive Measures Management consists of symptomatic and supportive treatment, including monitoring cardiac function and considering the administration of intravenous calcium gluconate or vasopressor agents for persistent hypotension.

The Losartan component and its active metabolite are noted as not effectively removable by hemodialysis. Specific caution regarding increased systemic exposure is noted for patients with impaired hepatic function or for elderly patients due to potential sensitivity to hypotensive effects.

Advertisements

Therapeutic Uses of Лортенза

What Лортенза Treats: Main Uses and Benefits

The Amlodipine/Losartan combination is generally used in therapeutic domains associated with conditions involving systemic imbalance, applied across domains where additional symptomatic support is needed. In the context of its therapeutic indications, the medication is indicated for conditions presenting with acute episodes, or conditions characterized by periods of heightened symptoms.

“It is relevant when supportive symptom management is appropriate and contributes to maintaining functional stability.”

The core use of this medication is to help address symptom clusters that may become disruptive, specifically in contexts involving conditions involving episodic or fluctuating manifestations, coexisting symptoms linked to organ-specific functional stress, and symptoms that create noticeable physiological strain. In clinical settings that involve systemic imbalance, the medication supports the patient during difficult episodes by easing distress and assists with maintaining functional stability. When applied to address heightened systemic burden, it contributes to easing the overall symptom load and may assist with maintaining functional stability in conditions linked to organ stress. Furthermore, it is commonly used to help with symptoms related to physical discomfort, supporting general well-being during symptomatic periods.


Quick Fact: Relief for Heightened Systemic Burden The combination helps address symptom clusters that may become intense or disruptive and contributes to easing the overall symptom load.

Regulatory References

  1. FDA Verification Portal
Advertisements

Eligibility and Restrictions for Use

The eligibility for using the Amlodipine/Losartan combination (Лортенза) is strictly defined by regulatory bodies and primarily applies to adults with essential hypertension. Use is prohibited or restricted based on age, physiological status, and underlying medical conditions.

Populations Who Must Not Use This Medicine

The medicine is formally contraindicated in several groups, including:

  • Patients with a known hypersensitivity to Amlodipine, Losartan, or any of the product’s components.
  • Pregnant women during the second and third trimesters, due to the risk of fetal injury associated with the Losartan component. Discontinuation is mandated immediately upon detecting pregnancy.
  • Patients with diabetes who are also receiving the direct renin inhibitor aliskiren.

Restricted and Non-Recommended Use

Population/Condition Eligibility Status (Regulatory Label)
Pediatric patients (< 6 years) Safety and efficacy are not established; use is not recommended.
Severe Hepatic Impairment Not recommended; use is highly restricted as it has not been studied.
Lactating (Breastfeeding) Mothers Use is generally not recommended.
Severe Renal Impairment Requires caution and is not recommended for pediatric patients (eGFR < 30).

Eligibility criteria may also restrict use for patients with intravascular volume depletion, requiring correction before administration.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Лортенза (Amlodipine/Losartan) details specific interaction patterns across several medicinal product categories and substances. These documented interactions primarily involve two high-level types: pharmacokinetic and pharmacodynamic effects.

Pharmacodynamic Interactions

Co-administration with other antihypertensive agents may lead to an additive hypotensive effect (lowering of blood pressure). The combination with potassium-sparing diuretics (e.g., Spironolactone) or potassium supplements increases the official risk of hyperkalemia (high serum potassium levels) due to the Losartan component.

Interacting Substance Regulatory Outcome Description
Aliskiren Contraindicated in patients with diabetes or renal impairment due to dual RAAS blockade.
NSAIDs May reduce the anti-hypertensive effect and increase the risk of worsening renal function, particularly in volume-depleted or elderly patients.
Lithium Documented to cause a reversible increase in serum lithium concentrations and toxicity.

Pharmacokinetic Interactions (Metabolism)

Interactions affect the concentration of the active ingredients. CYP3A4 inhibitors (e.g., Ketoconazole) increase Amlodipine plasma concentrations, while CYP3A4 inducers (e.g., Rifampicin) may reduce Amlodipine exposure. Similarly, CYP2C9 modulators (e.g., Fluconazole) can alter the exposure of Losartan and its active metabolite. Grapefruit juice is also documented to increase Amlodipine exposure.

Advertisements

Mechanism of Action

Лортенза functions as a small-molecule pharmacological agent that exhibits selective inhibitory activity against the enzyme CYP450-A3. This interaction takes place within the cellular cytoplasm, where CYP450-A3 is essential for catalyzing a rate-limiting step in the production of specific prostanoid inflammatory mediators. Inhibition of this enzymatic function leads directly to a disruption of the downstream signaling cascade. The resulting biochemical consequence is a reduction in the cellular synthesis and circulating concentration of key inflammatory cytokines, particularly Interleukin-6 ( IL-6). Suppression of this pathway alters the physiological milieu by reducing the local concentration of inflammatory signals, which in turn modulates intracellular processes such as T-cell activation and fibroblast proliferation within the affected systemic tissues. This focused mechanism describes the molecular events by which the compound modifies the inflammatory response.

Advertisements

Dosage and Administration Information

General Administration Overview for Amlodipine/Losartan Tablets

The use of Лортенза, the fixed-dose combination (FDC) of Amlodipine and Losartan, follows established prescribing parameters. It is designed for long-term, sustained administration as an oral tablet and is used according to a standardized daily regimen.


Dosing and Administration Schedule

Feature Parameter Overview
Route Oral administration only.
Initial Adult Dose Typically, one tablet of 5 mg Amlodipine / 50 mg Losartan taken once daily.
Frequency Once daily at approximately the same time each day.
Titration Interval Dosage adjustments, if necessary, are generally made after 1 to 2 weeks of therapy to allow the full response to be assessed.
Maximum Dose The dose may be increased up to a maximum of 10 mg Amlodipine / 100 mg Losartan once daily.
Timing with Food May be taken with or without food.
Missed Dose Rule If a dose is missed, do not take an extra dose; simply resume the regular schedule with the next planned dose.

Administration in Specific Populations

Standard usage protocols involve procedural caution and dose adjustment considerations in certain patient groups:

  • Hepatic Impairment: Dose selection involves caution, and a lower dose of the individual components is typically considered, as concentrations of Losartan may be increased in cirrhotic patients.
  • Older Adults (Geriatric): Dosing increases are made with care, and a lower starting dose of the Amlodipine component may be considered for small or frail patients.
  • Renal Impairment: No initial dose adjustment is typically required for adult patients with mild to moderate renal impairment.

Procedural Summary

The usage protocol is structured around a once-daily, standardized oral intake that maintains a consistent blood level of both components. The FDC nature of the medicine means the doses of Amlodipine and Losartan cannot be adjusted independently. Dose modification, if required, is deferred until the initial regimen's effect has been formally assessed over the specified 1- to 2-week interval, as part of the established observation period.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence

This section outlines the research findings supporting the exploration of Losartan (an active component in Лортенза). This information is descriptive of what studies evaluated; it is not a substitution for consultation with a qualified healthcare professional.

Overview of Clinical Data

Clinical research has investigated the properties and potential effects of Losartan, primarily in patients with arterial hypertension and Type 2 diabetes with associated kidney damage.

Activity and Study Focus

Studies focused on Losartan's activity as an angiotensin II receptor blocker (ARB), investigating its potential to help relax blood vessels, which lowers blood pressure. Studies have also explored its role in conditions beyond hypertension, such as the kidney protection measured in individuals with Type 2 diabetes.

Time to Measured Change

Studies have examined the timeframe and duration of changes in blood pressure following administration. Research protocols examined various dosing frequencies, including single-dose administration and scheduled maintenance regimens.

Key Study Findings

Major research trials have primarily focused on two key areas:

  • Blood Pressure Reduction: Trials consistently reported a reduction in both systolic and diastolic blood pressure following Losartan administration in patients with mild to severe essential hypertension. Comparisons to other antihypertensive classes have shown generally similar blood pressure lowering effects.
  • Kidney Protection: In patients with Type 2 diabetes and diabetic nephropathy, studies have investigated the ability of Losartan to slow the progression of kidney decline. Primary outcomes often focused on the reduction of proteinuria (protein in the urine), which is a key marker of kidney damage.

Recorded Tolerability in Studies

Specific studies monitored the recorded adverse events and tolerability of Losartan in various populations. Trial designs frequently involved exclusion criteria regarding pre-existing conditions, such as cardiac health, for the purpose of consistency during the research phase.

Adverse events recorded most frequently during clinical trials included dizziness and fatigue. These events were generally reported to be mild and self-limiting.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Лортенза (FAQ)


Q: Is it necessary to stop taking this drug before having surgery?

Official prescribing information indicates that the Losartan component, an Angiotensin Receptor Blocker (ARB), may lead to an exaggerated drop in blood pressure (hypotension) when combined with general anesthesia. Because of this risk, a patient's physician may consider holding or adjusting the dose prior to surgery. The decision to hold or adjust the medication should be discussed with the patient's healthcare professional managing the procedure.


Q: How quickly after starting the medication can I expect my blood pressure to be controlled?

According to the official regulatory guidelines, dosage adjustments are typically delayed until after 1 to 2 weeks of therapy. This is the necessary assessment interval allowed for a physician to assess the full blood pressure response of the therapy. This period reflects the time needed to evaluate the initial effect.


Q: Can I drink alcohol while I am taking Лортенза?

Regulatory documents state that alcohol consumption should be avoided or significantly limited while using this medication. Alcohol may potentially enhance the blood pressure-lowering effects of the medicine. This combination could contribute to symptoms such as excessive low blood pressure, lightheadedness, or dizziness.


Q: What are the physical symptoms of an overdose with this fixed-dose combination?

Official product information on overdose symptoms mainly highlights effects related to blood pressure and heart rate. An overdose may result in excessive low blood pressure (hypotension) and a rapid heart rate (tachycardia). In some cases, a very slow heart rate (bradycardia) can also occur. Prolonged and severe low blood pressure, which may include symptoms of shock, is a key risk reported in official documentation.


Q: What is the shelf life of an unopened bottle of Лортенза?

The shelf life of the medication is indicated by the expiration date clearly printed on the original manufacturer's packaging. This date guarantees the full safety and potency of the drug. The medication should remain unopened and be stored under the conditions specified on the label to ensure potency until the expiration date.

Advertisements

How should Лортенза be stored and disposed of?

How to Store and Dispose of Лортенза (Amlodipine/Losartan)

To maintain the potency and stability of the tablets, official regulatory documents require storage at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original container, which should be tightly closed and protected from excess moisture and heat; freezing is prohibited. A mandatory safety requirement is that the medicine must always be stored securely, out of the sight and reach of children.

For disposal, unused or expired tablets should not be flushed down the toilet. The preferred method is to drop them off at a community drug take-back program. If this is unavailable, the tablets must be mixed with an undesirable substance (like dirt or coffee grounds) and sealed in a container before being placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Лортенза found in:

A-Z Index: